JP2016501535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501535A5 JP2016501535A5 JP2015548014A JP2015548014A JP2016501535A5 JP 2016501535 A5 JP2016501535 A5 JP 2016501535A5 JP 2015548014 A JP2015548014 A JP 2015548014A JP 2015548014 A JP2015548014 A JP 2015548014A JP 2016501535 A5 JP2016501535 A5 JP 2016501535A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- nucleic acid
- composition
- recombinant nucleic
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 10
- 241000701022 Cytomegalovirus Species 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 241001502567 Chikungunya virus Species 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 241000725619 Dengue virus Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737094P | 2012-12-13 | 2012-12-13 | |
| US61/737,094 | 2012-12-13 | ||
| US201361881376P | 2013-09-23 | 2013-09-23 | |
| US61/881,376 | 2013-09-23 | ||
| US201361896646P | 2013-10-28 | 2013-10-28 | |
| US61/896,646 | 2013-10-28 | ||
| PCT/US2013/075137 WO2014093894A2 (en) | 2012-12-13 | 2013-12-13 | Dna antibody constructs and method of using same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019061531A Division JP2019115355A (ja) | 2012-12-13 | 2019-03-27 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2021016537A Division JP2021087433A (ja) | 2012-12-13 | 2021-02-04 | Ｄｎａ抗体構築物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501535A JP2016501535A (ja) | 2016-01-21 |
| JP2016501535A5 true JP2016501535A5 (enExample) | 2017-02-02 |
| JP6898060B2 JP6898060B2 (ja) | 2021-07-07 |
Family
ID=50935092
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548014A Active JP6898060B2 (ja) | 2012-12-13 | 2013-12-13 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2019061531A Pending JP2019115355A (ja) | 2012-12-13 | 2019-03-27 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2020035240A Pending JP2020108381A (ja) | 2012-12-13 | 2020-03-02 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2021016537A Withdrawn JP2021087433A (ja) | 2012-12-13 | 2021-02-04 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023040876A Pending JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023108341A Pending JP2023138998A (ja) | 2012-12-13 | 2023-06-30 | Ｄｎａ抗体構築物及びその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019061531A Pending JP2019115355A (ja) | 2012-12-13 | 2019-03-27 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2020035240A Pending JP2020108381A (ja) | 2012-12-13 | 2020-03-02 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2021016537A Withdrawn JP2021087433A (ja) | 2012-12-13 | 2021-02-04 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023040876A Pending JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023108341A Pending JP2023138998A (ja) | 2012-12-13 | 2023-06-30 | Ｄｎａ抗体構築物及びその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9994629B2 (enExample) |
| EP (1) | EP2931318A4 (enExample) |
| JP (6) | JP6898060B2 (enExample) |
| KR (4) | KR20150093834A (enExample) |
| CN (1) | CN104853782A (enExample) |
| AU (7) | AU2013358944B2 (enExample) |
| BR (2) | BR112015013700A8 (enExample) |
| CA (1) | CA2889723A1 (enExample) |
| EA (1) | EA201591131A1 (enExample) |
| HK (1) | HK1213481A1 (enExample) |
| MX (4) | MX2015007575A (enExample) |
| MY (1) | MY175708A (enExample) |
| SG (1) | SG10202002718RA (enExample) |
| WO (1) | WO2014093894A2 (enExample) |
| ZA (1) | ZA201503583B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2931318A4 (en) | 2012-12-13 | 2016-07-20 | Univ Pennsylvania | DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF |
| US10087240B2 (en) | 2013-12-13 | 2018-10-02 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
| KR20230145241A (ko) * | 2014-10-01 | 2023-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신 |
| CA2969214A1 (en) * | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| EP3365366B1 (en) | 2015-10-25 | 2021-07-14 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| CN109890407A (zh) * | 2016-03-21 | 2019-06-14 | 大卫·B·韦纳 | Dna抗体构建体和其使用方法 |
| FI3443006T3 (fi) | 2016-04-13 | 2023-10-23 | Sanofi Sa | Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja |
| KR102375327B1 (ko) * | 2016-05-05 | 2022-03-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 관문 분자를 표적으로 하는 dna 단클론성 항체 |
| SG10202011021XA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna monoclonal antibodies targeting influenza virus |
| SG10202011023YA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna monoclonal antibodies targeting il-6 and cd126 |
| EA201892525A1 (ru) | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
| CN110234346B (zh) * | 2016-09-19 | 2024-06-04 | 宾夕法尼亚大学理事会 | 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合 |
| TWI778985B (zh) | 2016-10-20 | 2022-10-01 | 法商賽諾菲公司 | 抗chikv抗體及其用途 |
| KR20230111264A (ko) * | 2016-11-07 | 2023-07-25 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| EP3606552A4 (en) * | 2017-04-07 | 2020-08-05 | The Rockefeller University | COMPOSITIONS AND METHODS RELATING TO HUMAN NEUTRALIZING ANTIBODIES DIRECTED AGAINST ZIKA VIRUS AND DENGUE VIRUS 1 |
| TWI673285B (zh) * | 2017-05-22 | 2019-10-01 | 國立成功大學 | 抗－登革熱病毒抗體、包含該抗體之藥學組合物及其用途 |
| WO2019067671A1 (en) * | 2017-09-27 | 2019-04-04 | David Weiner | DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST |
| WO2019152602A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Structurally modified flavivirus dmabs |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| AU2020323601A1 (en) * | 2019-07-31 | 2022-03-03 | The Wistar Institute Of Anatomy And Biology | Multivalent DNA antibody constructs and use thereof |
| TW202124722A (zh) | 2019-09-18 | 2021-07-01 | 美商英特佳樂帝克醫療公司 | 合成dna載體及其使用方法 |
| SE544000C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein |
| SE544001C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody |
| WO2021188906A1 (en) * | 2020-03-19 | 2021-09-23 | Nature's Toolbox, Inc. | Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same |
| KR20230011335A (ko) * | 2020-05-14 | 2023-01-20 | 이노비오 파마수티컬즈, 인크. | 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법 |
| EP4255484A4 (en) * | 2020-12-02 | 2025-02-26 | Thomas Jefferson University | DESMOGLEIN-2-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF USE |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI46572C (fi) * | 1972-04-07 | 1973-04-10 | Stroemberg Oy Ab | Jännitemuuntaja. |
| US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| CN1334343A (zh) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 抑制肿瘤生长的新抗体、其衍生物及其应用 |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| AU2003253447A1 (en) * | 2002-08-02 | 2004-02-23 | Yuhan Corporation | Expression vectors |
| CA2526120A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CN1480215A (zh) | 2003-07-07 | 2004-03-10 | 叶新新 | Sars病毒抗原抗体复合疫苗及实验动物模型与方法 |
| CN102344493B (zh) * | 2004-05-28 | 2014-09-03 | 艾更斯司股份有限公司 | 结合于psca蛋白的用于癌症诊断的抗体 |
| MXPA06013834A (es) | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
| EP1765846A4 (en) | 2004-07-13 | 2010-02-17 | Cell Genesys Inc | AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION |
| SI1771482T1 (sl) | 2004-07-22 | 2014-12-31 | Genentech, Inc. | Sestavek HER2 protitelesa |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2598454C (en) | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| CA2615983A1 (en) | 2005-07-21 | 2007-02-01 | Abbott Laboratories | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| JP2009171880A (ja) | 2008-01-23 | 2009-08-06 | Yokohama City Univ | アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発 |
| BRPI0909044B8 (pt) * | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| CN107083391A (zh) | 2008-04-04 | 2017-08-22 | 宾夕法尼亚大学托管会 | 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法 |
| US9073981B2 (en) | 2008-10-13 | 2015-07-07 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and use thereof |
| JP5758888B2 (ja) | 2009-07-06 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性ジゴキシゲニン結合抗体 |
| US9598676B2 (en) | 2009-07-13 | 2017-03-21 | Bharat Biotech International Limited | Composition useful as rotavirus vaccine and a method therefor |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| WO2011038290A2 (en) * | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| ES2826883T3 (es) * | 2009-10-14 | 2021-05-19 | Janssen Biotech Inc | Métodos de maduración por afinidad de anticuerpos |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| WO2012003995A1 (en) * | 2010-07-09 | 2012-01-12 | Cormus Srl | Lipid-conjugated antibodies |
| CA3062786C (en) | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| KR101939150B1 (ko) | 2010-11-12 | 2019-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| CN107090463A (zh) * | 2011-01-31 | 2017-08-25 | 宾夕法尼亚大学托管会 | 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法 |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| WO2012115980A1 (en) * | 2011-02-22 | 2012-08-30 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
| CN102199218A (zh) * | 2011-04-29 | 2011-09-28 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗Her2抗体-白细胞介素2融合蛋白及其用途 |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| EP2931318A4 (en) | 2012-12-13 | 2016-07-20 | Univ Pennsylvania | DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF |
| JP7078350B2 (ja) * | 2013-10-28 | 2022-05-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｄｎａ抗体構築物及びその使用方法 |
| AU2013358947B2 (en) | 2012-12-13 | 2016-10-20 | Inovio Pharmaceuticals, Inc. | WT1 vaccine |
| US20140377269A1 (en) | 2012-12-19 | 2014-12-25 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| US10087240B2 (en) | 2013-12-13 | 2018-10-02 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
-
2013
- 2013-12-13 EP EP13863143.7A patent/EP2931318A4/en active Pending
- 2013-12-13 AU AU2013358944A patent/AU2013358944B2/en active Active
- 2013-12-13 KR KR1020157018712A patent/KR20150093834A/ko not_active Ceased
- 2013-12-13 JP JP2015548014A patent/JP6898060B2/ja active Active
- 2013-12-13 KR KR1020237036307A patent/KR20230156146A/ko not_active Ceased
- 2013-12-13 CN CN201380065674.3A patent/CN104853782A/zh active Pending
- 2013-12-13 KR KR1020217020972A patent/KR20210088741A/ko not_active Ceased
- 2013-12-13 BR BR112015013700A patent/BR112015013700A8/pt not_active Application Discontinuation
- 2013-12-13 CA CA2889723A patent/CA2889723A1/en active Pending
- 2013-12-13 WO PCT/US2013/075137 patent/WO2014093894A2/en not_active Ceased
- 2013-12-13 MX MX2015007575A patent/MX2015007575A/es unknown
- 2013-12-13 EA EA201591131A patent/EA201591131A1/ru unknown
- 2013-12-13 US US14/651,740 patent/US9994629B2/en active Active
- 2013-12-13 HK HK16101459.4A patent/HK1213481A1/zh unknown
-
2014
- 2014-12-13 AU AU2014361811A patent/AU2014361811B2/en active Active
- 2014-12-13 MX MX2016007722A patent/MX388911B/es unknown
- 2014-12-13 MY MYPI2016702163A patent/MY175708A/en unknown
- 2014-12-13 BR BR112016013493-1A patent/BR112016013493B1/pt not_active IP Right Cessation
- 2014-12-13 KR KR1020167018560A patent/KR102454610B1/ko active Active
- 2014-12-13 SG SG10202002718RA patent/SG10202002718RA/en unknown
-
2015
- 2015-05-21 ZA ZA2015/03583A patent/ZA201503583B/en unknown
- 2015-06-12 MX MX2022016002A patent/MX2022016002A/es unknown
-
2016
- 2016-06-13 MX MX2021015971A patent/MX2021015971A/es unknown
- 2016-11-18 AU AU2016259451A patent/AU2016259451A1/en not_active Abandoned
-
2018
- 2018-04-30 AU AU2018202997A patent/AU2018202997A1/en not_active Abandoned
- 2018-06-12 US US16/005,997 patent/US20180346554A1/en not_active Abandoned
- 2018-09-26 US US16/142,457 patent/US11208470B2/en active Active
-
2019
- 2019-03-27 JP JP2019061531A patent/JP2019115355A/ja active Pending
- 2019-04-04 AU AU2019202343A patent/AU2019202343B2/en active Active
-
2020
- 2020-03-02 JP JP2020035240A patent/JP2020108381A/ja active Pending
- 2020-03-13 AU AU2020201853A patent/AU2020201853B2/en active Active
-
2021
- 2021-02-04 JP JP2021016537A patent/JP2021087433A/ja not_active Withdrawn
- 2021-06-03 AU AU2021203643A patent/AU2021203643A1/en not_active Abandoned
- 2021-12-17 US US17/554,642 patent/US20220112273A1/en not_active Abandoned
-
2023
- 2023-03-15 JP JP2023040876A patent/JP2023080085A/ja active Pending
- 2023-06-30 JP JP2023108341A patent/JP2023138998A/ja active Pending